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Abstract Prostaglandin E2 (PGE2)-dependent effects on var-
ious cell responses are regulated by respective PGE2 receptors
(EP1, EP2, EP3, EP4) expressing in target cells. Alveolar type II
cell (a main progenitor cell of lung adenocarcinoma) expressed
only EP4, while human lung adenocarcinoma cells (A549)
expressed EP3 as well as EP4. An antagonistic effect of EP3
against EP4 through the modulation of cyclic AMP level is
required for PGE2-mediated activation of Ras signal pathway in
A549 cells. These results suggest that the expression of EP3 may
be a critical factor for the PGE2-mediated activation of Ras
signal pathway in A549 cells. ß 2002 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
Lung cancer, particularly non-small cell lung cancer
(NSCLC), is one of the most common cancers and the leading
cause of cancer death in Western countries [1]. NSCLC ex-
hibiting adenocarcinoma histology is the majority of lung
cancers and its ras genes carry mutations [2]. Furthermore,
the presence of mutated ras genes in NSCLC is linked with
a shortened patient survival [3]. These reports means that
signaling pathways activated by oncogenic Ras proteins con-
tribute to the appearance of malignant phenotypes in lung
adenocarcinoma. In lung adenocarcinoma cells with Ras mu-
tations including A549 cells, the constitutive activation of Ras
signal pathway induces phospholipase A2 and cyclooxyge-
nase-2 (COX-2), and this induction is associated with a high
generation of prostaglandin E2 (PGE2) in the cells [4]. This
report also shows that inhibitors of PGE2 synthesis block
anchorage-independent growth of these cells. Thus, to esti-
mate the PGE2-dependent signals of lung adenocarcinoma
cells with oncogenic Ras proteins may lead to clari¢cation
of the Ras-stimulated signaling pathways governing the ap-
pearance of malignant phenotypes in NSCLC.
There are four subtypes of PGE2 receptors: EP1, EP2, EP3
and EP4, and di¡erent PGE2-dependent e¡ects are mediated
by the respective receptors that are expressed in the target
cells [5]. It has been well known that PGE2 formed by the
action of COX-2 participates in colon carcinogenesis [6]. A
recent report has shown that PGE2 via EP1 mediates carcino-
genic changes in the colon using knockout mice on PGE2
receptors [7]. These PGE2-mediated carcinogenic changes
may be based on the di¡erence of expression of EP1 between
normal and tumor cells. These reports suggest that the e¡ects
of PGE2 on the carcinogenesis ultimately depend on the ex-
pression patterns of PGE2 receptors in each tissue.
In this context, the present study was undertaken to esti-
mate the di¡erence of the expression patterns of PGE2 recep-
tors between A549 cells and human alveolar type II cells (a
main progenitor cell of lung adenocarcinoma), and there was
di¡erence about the expression patterns. Therefore, we tried
to clarify if the expressed PGE2 receptors-regulated signals in
A549 cells could contribute to stimulation of cell growth sig-
naling in order to clarify a exact role of PGE2 in the develop-
ment of lung adenocarcinoma.
2. Materials and methods
2.1. Cell culture and treatment
A549 cells (Riken cell bank, Saitama, Japan) were routinely grown
in Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% fetal
calf serum (FCS) and penicillin^streptomycin. In order to arrest cell
growth, 48 h starvation with low serum condition (0.02% FCS) was
carried out. After the starvation, PGE2 (Calbiochem, San Diego, CA,
USA) was added to culture medium. Pertussis toxin (PTX; Calbio-
chem) treatment was performed for 4 h before the stimulation of
PGE2. Isobutylmethylxanthine (IBMX; Calbiochem) was added for
30 min before the stimulation. C-Br-AMP (Calbiochem) was added
for 5 min before the stimulation.
2.2. RT-PCR
Messenger RNA was puri¢ed from freshly isolated human alveolar
type II and cultured A549 cells as described previously [8]. Transcripts
were ampli¢ed by RT-PCR using primers EP1 (NCBI reference num-
ber 13630896): sense primer (nucleotides 284^301), antisense primer
(nucleotides 1297^1317); EP2 (NCBI 4506254): sense primer (nucleo-
tides 168^188), antisense primer (nucleotides 760^780); EP3 (NCBI
13638343): sense primer (nucleotides 277^297), antisense primer (nu-
cleotide 1092^1112); EP4 (NCBI 4506258): sense primer (nucleotides
1334^1356), antisense primer (nucleotides 1664^1687); GAPDH
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(NCBI 7669491): sense primer (nucleotides 580^600), antisense primer
(nucleotides 809^829). GAPDH was used for an internal control.
After 35 cycles, PCR products were separated by electrophoresis
(1.5% agarose gel) and stained with GelStar (BMA, Rockland, ME,
USA). Wide-range DNA ladder (Takara, Shiga, Japan) was used as a
marker for sizing the PCR products. When negative results were ob-
served, fresh polymerase was added after 35 cycles, and the PCR was
continued to 70 cycles. Additionally, in order to con¢rm the perfor-
mance of PCR for EP1 and EP2, we carried out the PCR, using
complementary cDNA from human breast cancer cells as a positive
control (Fig. 2B).
2.3. Ras and Raf activation assay
The activation of Ras was determined according to an established
method [9]. To detect the active form of Ras (Ras-GTP), we used
GST-B-Raf RBD protein precoupled to glutathione^Sepharose beads.
GST-B-Raf RBD protein fusion proteins were isolated as described
previously [9]. Brie£y, sonicated bacteria were solubilized in 1% Tri-
ton X-100 and lysates were incubated with glutathione^Sepharose
overnight at 4‡C. Beads were washed with PBS and stored in 50%
glycerol at 320‡C. Cell lysates were prepared in RIPA bu¡er (25 mM
HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 10
mM MgCl2, 25 mM NaF, 10 mM Na3VO4, 1 mM PMSF, 1 mM
EDTA, 10 Wg/ml leupeptin, 10 Wg/ml aprotinin and 0.1% deoxycho-
late). After incubation of cell lysates with the beads at 4‡C for 2 h and
washing three times, bound proteins eluted in sample bu¡er, heated
for 5 min at 95‡C, separated on 12.5% SDS^PAGE, transferred to
nitrocellulose membrane and subjected to immunoblotting with anti-
Ras antibody (Transduction Labs, Lexington, KY, USA). Raf kinase
activity was determined using a single step assay for the kinase based
on phosphorylation of recombinant Mek-1, detected using an activa-
tion-speci¢c Mek antibody (New England Biolabs, Beverly, MA,
USA) that recognized Mek only when speci¢cally phosphorylated
by Raf [10]. Raf was immunoprecipitated from 500 Wg of lysate pro-
tein using sheep polyclonal anti-Raf antibody (UBI, Lake Placid, NY,
USA). An in vitro kinase assay was performed using recombinant
Mek-1 substrate (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
at 30‡C for 30 min. The reaction mixture contained Raf-1 immuno-
complex, 20 WM ATP, 500 ng of Mek-1 substrate, 20 mM NaCl, 1 mM
DTT, 10 mM MgCl2, 1 mM MnCl2 and 20 mM Tris^HCl bu¡er (pH
7.4). The samples were resolved by 10% SDS^PAGE and probed with
polyclonal anti-phosphorylated Mek (Mek-P; New England Biolabs),
polyclonal anti-Raf (Santa Cruz Biotechnology) and monoclonal anti-
Mek-1 (Transduction Labs, Lexington, KY, USA) antibodies. Detec-
tion was accomplished using ECL (Amersham, Piscataway, NJ, USA)
and a cooled CCD camera-linked Cool Saver system (Atto, Tokyo,
Japan). A two-dimensional densitometric evaluation of each band was
performed using ATTO Image Analysis Software (ATTO). Molecular
sizing was done using Rainbow molecular weight marker (Amer-
sham). Protein concentrations were determined using DC Protein As-
say (Bio-Rad, Hercules, CA, USA).
2.4. The assay of Mek and extracellular signal-regulated kinase (Erk)
activations
The activation of Mek and Erk were estimated by immunoblot
analysis using anti-Mek-P, phosphorylated Erk, Mek and Erk anti-
bodies (New England Biolabs). Cell lysates were resolved in 10%
SDS^PAGE, and subsequently each protein band was detected as
mentioned above.
2.5. Other assay
Cell growth was determined with Quick cell proliferation assay kit
using WST-1 reagent (MBL, Nagaoya, Japan). Cyclic AMP (cAMP)
level was determined with an ELISA kit (Cayman Chem, Ann Arbor,
MI, USA). Protein kinase A (PKA) activity was estimated with ME-
SACUP Protein Kinase Assay kit (MBL, Nagoya, Japan).
2.6. Statistical analysis
Data were analyzed by one-way analysis of variance followed by
Duncan’s multiple-range test. A P value of 0.05 or less was considered
signi¢cant.
3. Results and discussion
Initially, in order to check stimulating potential of PGE2 on
growth of A549 cells, we used a culture condition with low
serum level (serum concentration, 0.02%). We selected this
condition to maintain attachment of the cells for culture
dishes. As shown in Fig. 1A, cell growth of A549 cells was
stimulated by PGE2 in a dose-dependent manner. In similar
with cell growth, PGE2-dependent activation of the Ras path-
way in A549 cells occurred in a dose-dependent manner (Fig.
1B). These results suggest that the PGE2-induced cell prolif-
eration of A549 cells closely relates to the reinforcement of the
activation of the Ras signal pathway. This suggestion can be
supported by a previous report that the constitutive activation
of Ras pathway is necessary to maintain cell proliferation in
A549 cells [11]. PGE2 receptors are speci¢c members of a
Fig. 1. Dose dependency of PGE2 in cell growth (A) and the activation of Mek and Erk (B) in A549 cells. After 48 h starvation with low se-
rum condition (0.02% FCS), the cells were stimulated with various concentrations of PGE2 (0V1038) for 24 h and 10 min to determine cell
growth and the activation of Mek and Erk, respectively. Each value indicates the mean from ¢ve samples; vertical lines indicate S.E.M. *Sig-
ni¢cantly di¡erent (P6 0.05) from control. The results shown are representative of three independent experiments.
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group of heterotrimeric guanine nucleotide-binding regulatory
protein (G protein)-linked receptors [12], and the G protein-
dependent signals govern diversity of cell responses depending
on the expression patterns of the receptors in each cell [13].
Thus, it is ¢rstly required to determine the expressed PGE2
receptors in A549 cells in order to clarify a mechanism of
PGE2-induced activation of Ras signal pathway.
Next, by comparing the expression pattern of PGE2 recep-
tors in alveolar type II cells with A549 cells, we tried to esti-
mate which receptor(s) contributed to the PGE2-induced acti-
vation of Ras pathway in A549 cells. As shown in Fig. 2, only
the expression of EP4 was observed in alveolar type II cells,
while EP3 as well as EP4 was expressed in A549 cells. Thus, it
is possible that the expression of EP3 in A549 cells stimulates
the activation of the Ras pathway by in£uencing the EP4-de-
pendent signal pathway. In order to con¢rm this possibility,
we investigated the e¡ect of the expression of EP3 on EP4-
mediated signals in A549 cells. Of the known PGE2 receptors,
EP3 has been shown to be coupled to PTX-sensitive G protein
(Gi) [12], so we used PTX as a inhibitor against EP3 to esti-
mate a role of EP3 in PGE2-stimulated activation of Erk
signal pathway. As shown in Fig. 3A, TPX treatment abol-
ished the activation of Mek caused by PGE2 stimulation. EP4
has been reported to be coupled to Gs protein stimulating
adenylate cyclase (AC) and cAMP acts as a main signal in
the EP4-dependent signal pathway [14]. In contrast, EP3 has
been generally known to be coupled to Gi protein inhibiting
AC activity [15]. At least, we detected the expression of EP3-
Ia in A549 cells (data not shown), and it has been reported
that the EP3 subtype is coupled to PTX-sensitive Gi protein to
inhibit cAMP level [16,17]. These reports suggest that EP3
antagonizes the EP4-dependent signal pathway through the
regulation of cAMP level. In order to ascertain this possibil-
ity, we compared the PGE2-induced change of cAMP level of
PTX-treated cells with that of non-treated cells. The level of
cAMP in the PTX-treated group showed a signi¢cant increase
by PGE2 stimulation, while the level in the non-treated group
did not show any change by the stimulation (Fig. 3B). A EP3/
EP1 agonist, sulprostone, stimulation also induced the reduc-
tion of cAMP level comparing with control (data not shown).
In addition, a cAMP analogue, 8-Br-cAMP and a phospho-
diesterase inhibitor, IBMX, suppressed PGE2-dependent acti-
vation of Mek (Fig. 4). These two data further support the
above possibility. Taking together, it seems that antagonistic
e¡ect of EP3 against EP4 leads to reinforcement of the acti-
vation of the Ras signal pathway due to the regulation of
cAMP level in A549 cells stimulated with PGE2.
Finally, we tried to determine which molecule of the Ras
signal pathway was mainly regulated via the PGE2 receptors
in A549 cells after the stimulation of PGE2. As shown in Fig.
5A,B, PTX treatment did not a¡ect the activation of Ras, but
cancelled the PGE2-dependent activation of Raf. These results
suggest that EP3 in A549 cells reinforces the activation of the
Ras signal pathway by interfering with EP4-dependent sup-
pression of Raf activity. Since it has been reported that Raf
activity is inhibited by PKA [17], this inhibitory e¡ect may
Fig. 2. RT-PCR analyses for each receptor in alveolar type II and A549 cells (A), and for EP1 and EP2 in human breast cancer cells (B).
A: M, Size marker; 1, GAPDH; 2, EP1 ; 3, EP2 ; 4, EP3 ; 5, EP4. The results shown are representative of three independent experiments. B: M,
Size marker; 1,2, GAPDH; 3,4, EP1 ; 5,6, EP2.
Fig. 3. The e¡ects of PTX on the activation of Mek (A) and cAMP level (B). The cells were cultured and treated in the same condition with
Fig. 1 except PTX treatment. PTX treatment (400 ng/ml) and PGE2 stimulation (1038 M) were carried out as described in Section 2. PTX,
PTX-treated group; Non, non-treated group; U, unstimulated group by PGE2 ; S, stimulated group by PGE2. Each value indicates the mean
from ¢ve samples; vertical lines indicate standard error. *Signi¢cantly di¡erent (P6 0.05) from control. The results shown are representative of
three independent experiments.
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depend on the activation of PKA. In fact, PKA activity
showed a signi¢cant increase by PTX treatment (Fig. 5C).
From our present data and previous reports [5,18,19], we
propose a possible mechanism on the PGE2-dependent acti-
vation of the Ras signal pathway in A549 cells. The constitu-
tive activation of Ras induces phospholipase A2 and COX-2,
and this induction is associated with a high generation of
PGE2 in these cells. When this produced PGE2 stimulates
EP3, the activation of GK-subunit of G protein coupled to
EP3 decreases the cAMP level via the inhibition of AC activ-
ity. As well, EP3 activates the Ras signal pathway through the
activation of GLQ-subunit of G protein. In contrast, PGE2-
stimulated EP4 induces an elevation of the cAMP level via the
activation of AC activity and subsequent activation of PKA.
The activated PKA causes the inactivation of the Ras signal
pathway through the inhibition of Raf activity. Taking to-
gether, it seems that the expression of EP3 in A549 cells con-
tributes to the activation of the Ras signal pathway by sup-
pressing the EP4-induced increase of cAMP level via the
inhibition of AC activity. Thus, the selective inhibition of
the EP3-dependent signal pathway in the lung adenocarcino-
ma cells is directly linked with the suppression of the Ras
signal pathway. Since the blockade of the Ras signal pathway
e¡ectively suppresses the growth of tumors that constitutively
activate the pathway [20,21], the idea for targeting EP3 may
lead to the development of new drugs for lung adenocarcino-
ma prevention and therapy.
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Fig. 4. The e¡ects of c-Br-AMP and IBMX on the activation of
Mek. The cells were cultured and treated in the same condition
with Fig. 1 except c-Br-AMP and IBMX treatments. C-Br-AMP
(100 WM), IBMX treatments (100 WM) and PGE2 stimulation
(1038 M) were carried out as described in Section 2. The results
shown are representative of three independent experiments.
Fig. 5. The e¡ects of PTX on the activation of Ras (A), the activities of Raf kinase (B) and PKA (C). The cells were cultured and treated in
the same condition as mentioned in Fig. 3. A,B: The activation of Ras and Raf activity were determined as described in Section 2. PTX, PTX-
treated group; Non, non-treated group; U, unstimulated group by PGE2 ; S, stimulated group by PGE2. C: Each value indicates the mean
from ¢ve samples; vertical lines indicate standard error. *Signi¢cantly di¡erent (P6 0.05) from control. The results shown are representative of
three independent experiments.
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